Blockade of gap junction hemichannel suppresses disease progression in mouse models of amyotrophic lateral sclerosis and Alzheimer's disease

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Takeuchi, Hideyuki ^a   Mizoguchi, Hiroyuki ^a   Doi, Yukiko ^a   Jin, Shijie ^a   Noda, Mariko ^a   Liang, Jianfeng ^a   Li, Hua ^a   Zhou, Yan ^a   Mori, Rarami ^a   Yasuoka, Satoko ^a   Li, Endong ^a   Parajuli, Bijay ^a   Kawanokuchi, Jun ^a   Sonobe, Yoshifumi ^a   Sato, Jun ^a   Yamanaka, Koji ^b   Sobue, Gen ^c   Mizuno, Tetsuya ^a   Suzumura, Akio ^a  

^a NAGOYA UNIVERSITY   (Japan)

^b RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CARBENOXOLONE; CARBENOXOLONE DERIVATIVE; COPPER ZINC SUPEROXIDE DISMUTASE; GAP JUNCTION HEMICHANNEL; GAP JUNCTION PROTEIN; GLUTAMIC ACID; GLYCYRRHETINIC ACID; INI 0602; PRESENILIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; DRUG DERIVATIVE; ION CHANNEL; SOD1 G37R PROTEIN, MOUSE; SOD1 G93A PROTEIN; SUPEROXIDE DISMUTASE;

ALZHEIMER DISEASE; AMNESIA; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; COPY NUMBER VARIATION; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG EFFICACY; ENZYME INHIBITION; ENZYME RELEASE; EXCITOTOXICITY; GENETIC VARIABILITY; GLIOSIS; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE PERMEABILITY; MICROGLIA; MOUSE; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; TRANSGENE; TREATMENT RESPONSE; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; CELL JUNCTION; CHEMISTRY; CYTOLOGY; DISEASE COURSE; FEMALE; GENETICS; HUMAN; MALE; MEMORY DISORDER; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPINAL CORD; TRANSGENIC MOUSE;

MUS MUSCULUS;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTI-INFLAMMATORY AGENTS; BEHAVIOR, ANIMAL; CARBENOXOLONE; DISEASE PROGRESSION; FEMALE; GAP JUNCTIONS; GLYCYRRHETINIC ACID; HUMANS; ION CHANNELS; MALE; MEMORY DISORDERS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROGLIA; SPINAL CORD; SUPEROXIDE DISMUTASE;

EID: 79959359691     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021108     Document Type: Article

References (65)

1. Block ML, Zecca L, Hong JS, (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8: 57-69.
2. Kempermann G, Neumann H, (2003) Neuroscience. Microglia: the enemy within? Science 302: 1689-1690.
3. Bruijn LI, Miller TM, Cleveland DW, (2004) Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 27: 723-749.
4. McGeer PL, McGeer EG, (2002) Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 26: 459-470.
5. Takeuchi H, Jin S, Wang J, Zhang G, Kawanokuchi J, et al. (2006) Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J Biol Chem 281: 21362-21368.
6. Takeuchi H, Mizuno T, Zhang G, Wang J, Kawanokuchi J, et al. (2005) Neuritic beading induced by activated microglia is an early feature of neuronal dysfunction toward neuronal death by inhibition of mitochondrial respiration and axonal transport. J Biol Chem 280: 10444-10454.
7. Barger SW, Basile AS, (2001) Activation of microglia by secreted amyloid precursor protein evokes release of glutamate by cystine exchange and attenuates synaptic function. J Neurochem 76: 846-854.
8. Piani D, Spranger M, Frei K, Schaffner A, Fontana A, (1992) Macrophage-induced cytotoxicity of N-methyl-D-aspartate receptor positive neurons involves excitatory amino acids rather than reactive oxygen intermediates and cytokines. Eur J Immunol 22: 2429-2436.
9. Lobsiger CS, Cleveland DW, (2007) Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat Neurosci 10: 1355-1360.
10. Nelson PT, Soma LA, Lavi E, (2002) Microglia in diseases of the central nervous system. Ann Med 34: 491-500.
11. Suzumura A, Takeuchi H, Zhang G, Kuno R, Mizuno T, (2006) Roles of glia-derived cytokines on neuronal degeneration and regeneration. Ann N Y Acad Sci 1088: 219-229.
12. Parsons CG, Stoffler A, Danysz W, (2007) Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology 53: 699-723.
13. Kipnis J, Avidan H, Caspi RR, Schwartz M, (2004) Dual effect of CD4+CD25+ regulatory T cells in neurodegeneration: a dialogue with microglia. Proc Natl Acad Sci U S A 101 (Suppl 2): 14663-14669.
14. Koenigsknecht J, Landreth G, (2004) Microglial phagocytosis of fibrillar beta-amyloid through a beta1 integrin-dependent mechanism. J Neurosci 24: 9838-9846.
15. Schwab JM, Schluesener HJ, (2004) Microglia rules: insights into microglial-neuronal signaling. Cell Death Differ 11: 1245-1246.
16. Zietlow R, Dunnett SB, Fawcett JW, (1999) The effect of microglia on embryonic dopaminergic neuronal survival in vitro: diffusible signals from neurons and glia change microglia from neurotoxic to neuroprotective. Eur J Neurosci 11: 1657-1667.
17. Leigh PN, Swash M, Iwasaki Y, Ludolph A, Meininger V, et al. (2004) Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial. Amyotroph Lateral Scler Other Motor Neuron Disord 5: 84-98.
18. Yamamoto M, Tanaka F, Tatsumi H, Sobue G, (2008) A strategy for developing effective amyotropic lateral sclerosis pharmacotherapy: from clinical trials to novel pharmacotherapeutic strategies. Expert Opin Pharmacother 9: 1845-1857.
19. Orrell RW, (2010) Motor neuron disease: systematic reviews of treatment for ALS and SMA. Br Med Bull 93: 145-159.
20. Laird DW, (2009) The gap junction proteome and its relationship to disease. Trends Cell Biol.
21. Liang J, Takeuchi H, Doi Y, Kawanokuchi J, Sonobe Y, et al. (2008) Excitatory amino acid transporter expression by astrocytes is neuroprotective against microglial excitotoxicity. Brain Res 1210: 11-19.
22. Yawata I, Takeuchi H, Doi Y, Liang J, Mizuno T, et al. (2008) Macrophage-induced neurotoxicity is mediated by glutamate and attenuated by glutaminase inhibitors and gap junction inhibitors. Life Sci 82: 1111-1116.
23. Takeuchi H, Jin S, Suzuki H, Doi Y, Liang J, et al. (2008) Blockade of microglial glutamate release protects against ischemic brain injury. Exp Neurol 214: 144-146.
24. Jin S, Takeuchi H, Yawata I, Harada Y, Sonobe Y, et al. (2009) Blockade of glutamate release from microglia attenuates experimental autoimmune encephalomyelitis in mice. Tohoku J Exp Med 217: 87-92.
25. Juszczak GR, Swiergiel AH, (2009) Properties of gap junction blockers and their behavioural, cognitive and electrophysiological effects: animal and human studies. Prog Neuropsychopharmacol Biol Psychiatry 33: 181-198.
26. Prokai L, Prokai-Tatrai K, Bodor N, (2000) Targeting drugs to the brain by redox chemical delivery systems. Med Res Rev 20: 367-416.
27. Boillee S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, et al. (2006) Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312: 1389-1392.
28. Hori N, Carpenter DO, (1994) Functional and morphological changes induced by transient in vivo ischemia. Exp Neurol 129: 279-289.
29. Saito Y, Kawashima A, Ruberu NN, Fujiwara H, Koyama S, et al. (2003) Accumulation of phosphorylated alpha-synuclein in aging human brain. J Neuropathol Exp Neurol 62: 644-654.
30. Delisle MB, Carpenter S, (1984) Neurofibrillary axonal swellings and amyotrophic lateral sclerosis. J Neurol Sci 63: 241-250.
31. Takahashi T, Yagishita S, Amano N, Yamaoka K, Kamei T, (1997) Amyotrophic lateral sclerosis with numerous axonal spheroids in the corticospinal tract and massive degeneration of the cortex. Acta Neuropathol 94: 294-299.
32. Dickson TC, King CE, McCormack GH, Vickers JC, (1999) Neurochemical diversity of dystrophic neurites in the early and late stages of Alzheimer's disease. Exp Neurol 156: 100-110.
33. Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, et al. (1997) Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19: 939-945.
34. Doi Y, Mizuno T, Maki Y, Jin S, Mizoguchi H, et al. (2009) Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid b neurotoxicity in in vitro and in vivo models of Alzheimer's disease. Am J Pathol 175: 2121-2132.
35. De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, et al. (2007) Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 282: 11590-11601.
36. Deshpande A, Mina E, Glabe C, Busciglio J, (2006) Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J Neurosci 26: 6011-6018.
37. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, et al. (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-539.
38. Newsholme P, Newsholme EA, (1989) Rates of utilization of glucose, glutamine and oleate and formation of end-products by mouse peritoneal macrophages in culture. Biochem J 261: 211-218.
39. Newsholme EA, Calder PC, (1997) The proposed role of glutamine in some cells of the immune system and speculative consequences for the whole animal. Nutrition 13: 728-730.
40. Yudkoff M, (1997) Brain metabolism of branched-chain amino acids. Glia 21: 92-98.
41. Nissim I, (1999) Newer aspects of glutamine/glutamate metabolism: the role of acute pH changes. Am J Physiol 277: F493-497.
42. Eugenin EA, Eckardt D, Theis M, Willecke K, Bennett MV, et al. (2001) Microglia at brain stab wounds express connexin 43 and in vitro form functional gap junctions after treatment with interferon-gamma and tumor necrosis factor-alpha. Proc Natl Acad Sci U S A 98: 4190-4195.
43. Chanson M, Derouette JP, Roth I, Foglia B, Scerri I, et al. (2005) Gap junctional communication in tissue inflammation and repair. Biochim Biophys Acta 1711: 197-207.
44. Frantseva MV, Kokarovtseva L, Perez Velazquez JL, (2002) Ischemia-induced brain damage depends on specific gap-junctional coupling. J Cereb Blood Flow Metab 22: 453-462.
45. Rawanduzy A, Hansen A, Hansen TW, Nedergaard M, (1997) Effective reduction of infarct volume by gap junction blockade in a rodent model of stroke. J Neurosurg 87: 916-920.
46. Cotrina ML, Kang J, Lin JH, Bueno E, Hansen TW, et al. (1998) Astrocytic gap junctions remain open during ischemic conditions. J Neurosci 18: 2520-2537.
47. Perez Velazquez JL, Carlen PL, (2000) Gap junctions, synchrony and seizures. Trends Neurosci 23: 68-74.
48. Fujita K, Nakanishi K, Sobue K, Ueki T, Asai K, et al. (1998) Astrocytic gap junction blockage and neuronal Ca2+ oscillation in neuron-astrocyte cocultures in vitro. Neurochem Int 33: 41-49.
49. Di Giorgio FP, Carrasco MA, Siao MC, Maniatis T, Eggan K, (2007) Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat Neurosci 10: 608-614.
50. Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, et al. (2007) Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 10: 615-622.
51. Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, et al. (2008) Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 11: 251-253.
52. Haughey NJ, Mattson MP, (2003) Alzheimer's amyloid beta-peptide enhances ATP/gap junction-mediated calcium-wave propagation in astrocytes. Neuromolecular Med 3: 173-180.
53. Vernadakis A, (1996) Glia-neuron intercommunications and synaptic plasticity. Prog Neurobiol 49: 185-214.
54. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, et al. (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64: 1553-1562.
55. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, et al. (2008) Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372: 216-223.
56. Pop V, Head E, Hill MA, Gillen D, Berchtold NC, et al. (2010) Synergistic Effects of Long-Term Antioxidant Diet and Behavioral Enrichment on {beta}-Amyloid Load and Non-Amyloidogenic Processing in Aged Canines. J Neurosci 30: 9831-9839.
57. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, et al. (1994) Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264: 1772-1775.
58. Suzumura A, Mezitis SG, Gonatas NK, Silberberg DH, (1987) MHC antigen expression on bulk isolated macrophage-microglia from newborn mouse brain: induction of Ia antigen expression by gamma-interferon. J Neuroimmunol 15: 263-278.
59. Contreras JE, Saez JC, Bukauskas FF, Bennett MV, (2003) Gating and regulation of connexin 43 (Cx43) hemichannels. Proc Natl Acad Sci U S A 100: 11388-11393.
60. Pelegrin P, Surprenant A, (2006) Pannexin-1 mediates large pore formation and interleukin-1beta release by the ATP-gated P2X7 receptor. EMBO J 25: 5071-5082.
61. Jin S, Kawanokuchi J, Mizuno T, Wang J, Sonobe Y, et al. (2007) Interferon-beta is neuroprotective against the toxicity induced by activated microglia. Brain Res 1179: 140-146.
62. Hayworth CR, Gonzalez-Lima F, (2009) Pre-symptomatic detection of chronic motor deficits and genotype prediction in congenic B6.SOD1(G93A) ALS mouse model. Neuroscience 164: 975-985.
63. Mizoguchi H, Yamada K, Niwa M, Mouri A, Mizuno T, et al. (2007) Reduction of methamphetamine-induced sensitization and reward in matrix metalloproteinase-2 and-9-deficient mice. J Neurochem 100: 1579-1588.
64. Waza M, Adachi H, Katsuno M, Minamiyama M, Sang C, et al. (2005) 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med 11: 1088-1095.
65. Mouri A, Noda Y, Hara H, Mizoguchi H, Tabira T, et al. (2007) Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. FASEB J 21: 2135-2148.